Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL62 in Systemic Lupus Erythematosus
NCT05796206Phase 2Completed
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing MIL62 with Placebo (2 arms). Primary endpoint: Systemic Lupus Erythematosus Responder Index 4 at 12 weeks. Started May 2023; status: completed.
02
Drugs
Bejescin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05796206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05796206.